期刊文献+

血清HE4、CA125与TSGF对卵巢癌诊断的价值分析 被引量:1

下载PDF
导出
摘要 目的:分析联合检测血清人附睾蛋白4(HE4)、肿瘤抗原(CA125)以及肿瘤特异性生长因子(TSGF)在卵巢癌诊断中的应用价值。方法:选取2013年12月-2015年10月收住我院的卵巢癌患者72例,依据病变程度将其分为早期(Ⅰ期)组32例,中晚期(Ⅱ、Ⅲ期)组40例;同期于我院确诊的卵巢良性肿瘤患者62例为对照组。分别采用ELISA法、化学显色法以及电化学发光免疫分析法检测并比较三组患者间HE4、CA125及TSGF水平,比较组间差异。同时对HE4、CA125及TSGF与卵巢癌淋巴结转移关系进行观察。结果:早期组患者HE4、CA125及TSGF均高于对照组(P<0.05),但低于中晚期组(P<0.05),差异有统计学意义。HE4、CA125及TSGF水平在发生淋巴结转移的卵巢癌患者中均显著升高(P<0.05)。结论:联合检测HE4、TSGF和CA125有助于卵巢癌的诊断,并可在一定程度上预测病变程度。
出处 《医学理论与实践》 2017年第9期1367-1368,共2页 The Journal of Medical Theory and Practice
  • 相关文献

参考文献5

二级参考文献48

  • 1Bilici A,Ustaalioglu BB,Seker M.Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer:Is there an impact of FDG PET/CT on patient management[J].European Journal of Nuclear Medicine and Molecular Imaging,2010,37(5):1259-1269.
  • 2DeToledo MCS,Sarian,LO,Sallum,LF.et al.Analysis of the contribution of immunologically-detectable HER2,steroid receptors and of the "triple-negative" tumor sta- tus to disease-free and overall survival of women with epithelial ovarian cancei[J].Acta Histochemica:Zeitschrift fur Histologische Topochemie,2014,116(3);440-447.
  • 3Richard G. Moore,Amy K. Brown,M. Craig Miller,Steven Skates,W. Jeffrey Allard,Thorsten Verch,Margaret Steinhoff,Geralyn Messerlian,Paul DiSilvestro,C.O. Granai,Robert C. Bast.The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecologic Oncology . 2007 (2)
  • 4Li J,Dowdy S,Tipton T,et al. HE4 as a biomarker forovarian and endometrial cancer management[J]. Expert RevMol Diagn, 2009, 9(6):555- 566.
  • 5Hellstr6m I, Raycraft J, Haydcn ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma[J]. Canc- er Res,2003,63(13) :3695-3700.
  • 6Bunger S,Laubert T,Roblick UJ, et al. Serum biomarkers for im- proved diagnostic o{ pancreatic cancer; a current overview[J]. J Cancer Res Clin Oncol,2011,137(3):375-389.
  • 7DengB, TanQY, FanXQ, et al. Clinlcal value of assaying tumor supplied group of factor/tumor specific growth factor in patients with solitary pulmonary nodule[J]. Clin Lung Cancer, 2011,12 (3) :192-196.
  • 8Duffy M J, Bonfrer J M, Kulpa J, et al. CA125 ovariancancer : Eu ropean Group on Tumor Markers guidelines forclinical use[J]. Int J Gyneeol Cancer, 2005,15(5) : 679-691.
  • 9HellstrOm I, Raycraft J, tIayden ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma[J]. Cancer Res,2003,63(13) :3695-3700.
  • 10Kirchhoff C. Molecular characterization of epididymalproteins [J]. Rev Reprod,1998,3(2) 86-95.

共引文献26

同被引文献41

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部